$LUNG

Biotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

Pulmonx (Nasdaq: LUNG) reported Q2 2026 revenue of $22.8 million, down 5% year over year, with U.S. revenue at $14.2 million (-4%) and international at $8.6 million (-6%). Gross margin rose to 78%. Net loss was $10.1 million, down from $15.2 million. Full-year 2026 revenue guidance is $90 million to $92 million.

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 765,721 shares of Pulmonx Corp common stock, or 1.8% of the class. The filing states BlackRock has sole voting and sole dispositive power over the shares, with no shared power. It also notes underlying clients may receive dividends or sale proceeds.

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 5,969 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 3,684 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 2,153 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 2,691 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.